Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for diseases or other public health threats for civilian, government and military use. Co.'s U.S. Food and Drug Administration approved commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens. SEYSARA® (sarecycline) is being marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. We show 33 historical shares outstanding datapoints in our coverage of PRTK's shares outstanding history.
Understanding the changing numbers of PRTK shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PRTK versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PRTK by allowing them to research PRTK shares outstanding history
as well as any other stock in our coverage universe. |
Free PRTK Email Alerts:
Video: Shares Outstanding Importance
